Showing results (321-330 of 344) with videos related to

Sort By:
Pageof 35
World Journal of Gastroenterology|April 21, 2015
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinomaMin-Young Lee, Ki Sun Jung, Hae Su Kim, et al.
Nature Communications|May 10, 2020
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinomaNayoung Kim, Hong Kwan Kim, Kyungjong Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2022
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLCHyun Ae Jung, Jinyeong Lim, Yoon-La Choi, et al.
Cancer Immunology, Immunotherapy : CII|October 9, 2024
Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancerHye In Kim, Won Gu Kim, Mijin Kim, et al.
Lancet (London, England)|August 29, 2021
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyJong-Mu Sun, Lin Shen, Manish A Shah, et al.
Eclinicalmedicine|June 17, 2025
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trialJhingook Kim, Yeong Hak Bang, Sehhoon Park, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 27, 2015
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)Ji Yun Lee, Jong-Mu Sun, Dong Ryul Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.
JTO Clinical and Research Reports|December 2, 2024
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18Dae-Ho Choi, Miso Kim, Young Saing Kim, et al.
Elife|November 8, 2024
Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerNayoung Kim, Sehhoon Park, Areum Jo, et al.
Pageof 35